title: Decrease in the size of ovarian endometriomas during ovarian suppression in stage IV endometriosis. Role of preoperative medical treatment.
abstract: OBJECTIVE
  To evaluate the effect of hormonal suppression on the size of ovarian endometriomas and to develop a predictive model for changes in the size of these lesions.
  
  
  METHODS
  The study consisted of 80 women of reproductive age with the diagnosis of stage IV pelvic endometriosis, according to the revised American Fertility Society (rAFS) classification, and included 48 women with endometriomas > or = 3 cm. After the initial laparoscopic and sonographic evaluation, ovarian suppression was achieved with either danazol or a gonadotropin-releasing hormone agonist (GnRH-a) for six months. In all patients, pretreatment and posttreatment pelvic sonograms were performed, and at the end of treatment residual disease was evaluated and resected by laparotomy or laparoscopy. Seven of 80 women with endometriomas > or = 3 cm had serial sonograms during the course of therapy. Serial pelvic sonograms in this subgroup were used to develop a statistical model for predicting the size of endometriomas after treatment. The model was then tested in another subgroup of 41 women with endometriomas > or = 3 cm.
  
  
  RESULTS
  At the end of treatment, there was a significant decrease in the r-AFS score in both the danazol and GnRH-a groups. Medical treatment facilitated surgical resection of residual disease and preservation of ovarian tissue. There was no difference in this respect between danazol and GnRH-a. Endometriomas decreased by 51% in both treatment groups. The predictive model, when tested on 41 patients, underestimated the actual change by 11%, but the difference was within the 95% confidence limits.
  
  
  CONCLUSIONS
  This study documented, for the first time, that ovarian endometriomas decrease in size during hormonal suppression. Both danazol and GnRH-a were equally effective.
authors.affiliation: Institute for the Study and Treatment of Endometriosis, Rush Medical College, Chicago, Illinois 60614, USA.
authors.forename: N
authors.initials: N
authors.lastname: Rana
authors.forename: S
authors.initials: S
authors.lastname: Thomas
authors.forename: C
authors.initials: C
authors.lastname: Rotman
authors.forename: W P
authors.initials: WP
authors.lastname: Dmowski
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003613:Danazol / Q000627:therapeutic use*; D004715:Endometriosis / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D010535:Laparoscopy; D007813:Laparotomy; D016729:Leuprolide / Q000627:therapeutic use*; D010049:Ovarian Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D011300:Preoperative Care; D011446:Prospective Studies; D012044:Regression Analysis; D014463:Ultrasonography
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide; D003613:Danazol